Entries in Medincine (1)


FDA Committee to Review Osteoporosis Drug Safety

File photo. D-BASE/Getty Images(WASHINGTON) -- A U.S. Food and Drug Administration advisory committee will meet Friday to review the safety of a popular class of osteoporosis drugs called bisphosphonates amid worry that their long-term use could cause rare fractures of the thighbones and death of the jawbone.

According to The Wall Street Journal, the committee plans to evaluate whether women should temporarily stop using the drugs or use them for only a few years. The FDA did not immediately respond to ABC News' requests for comment.

In September, a report by the American Society of Bone and Mineral Research linked bisphosphonates, which include the drugs Fosamax and its generic counterparts, Boniva and Actonel, to rare femur fractures among patients with osteoporosis. Of 310 cases, 94 percent of the patients were taking bisphosphonates.

While the report's authors did not say that the osteoporosis medications caused the fractures, they recommended that the FDA change the drugs' labeling to warn patients about the possible risks.

"Based on the report, we now feel that there is a definitive relationship between these class of drugs and these fractures, and it's even stronger in those taking those drugs for a long time," Dr. Elizabeth Shane, a co-author and professor of medicine at Columbia University College of Physicians and Surgeons, told ABC News.

But she also said bisphosphonates could help prevent other types of fractures, and patients should still take them. She continues to prescribe bisphosphonates and evaluates each patient individually. Patients who take them, however, should be aware of warning signs, such as a hip, thigh or groin pain.

Many doctors are changing the way they prescribe bisphosphonates, taking patients off the drugs after two or three years. Others recommend a five-year limit.

Fosamax, a blockbuster drug that has earned billions for Merck and Co., has also been linked to severe muscle pain and osteonecrosis of the jaw, also known as jawbone death

Merck responded to the initial reports of jawbone death by saying the clinical information was inconclusive.

"In worldwide post-marketing experience with Fosamax, Fosamax Plus D, rare reports consistent with osteonecrosis of the jaw have been received. Many of these reports lack sufficient clinical details to make definitive assessments or are confounded, particularly since a generally accepted definition of ONJ in the general population is unknown," Merck wrote in a statement.

Copyright 2011 ABC News Radio

ABC News Radio